Sign In
Last checked at 
26 Mar 2025 07:00
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
PDMR/Director Dealings
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that on Tuesday 25 March 2025, the following members of the EKF Board purchased 550,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 22.0 pence per Ordinary Share:
Director | Title | Number of Ordinary Shares purchased | Resulting holding in Ordinary Shares | Percentage of issued share capital |
Julian Baines | Executive Chair | 50,000 | 1,666,288 | 0.37% |
Gavin Jones | Chief Executive Officer | 50,000 | 50,000 | 0.01% |
Stephen Young | Chief Financial Officer | 50,000 | 135,000 | 0.03% |
Christopher Mills¹ | Non-Executive Director | 150,000 | 133,500,000 | 29.42% |
Christian Rigg | Non-Executive Director | 100,000 | 100,000 | 0.02% |
Jennifer Winter | Non-Executive Director | 150,000 | 150,000
| 0.03% |
¹Includes direct and indirect interests in the Company
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
Julian Baines, Executive Chair | Tel: +44 (0)29 2071 0570 | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
Phil Davies / Oliver Platts | |||
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About EKF Life Sciences
EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical, and industrial applications.
EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.
Utilising its unique technical expertise, the EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.
EKF Life Sciences has two state-of-the-art GMP manufacturing facilities, located within close proximity, in Elkhart and South Bend Indiana, one the US's major life sciences and industrial hotspots. It operates to the highest regulatory standards under cGMP principles, FDA certification and ISO 13485 Quality Program. The facilities include bioreactors ranging from 5L to 14,500L, enabling it to offer an end-to-end service from bench/proof-of-concept through to full scale commercial production, providing its customers with desired yields, precision at scale and cost-efficiency.
EKF Lifesciences is also one of the market leaders for the supply of β-HB, a reagent used to detect ketones for patients suffering from diabetic ketoacidosis, as well as many other clinical applications.
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges.
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| 1. Julian Baines 2. Gavin Jones 3. Stephen Young 4. Christopher Mills 5. Christian Rigg 6. Jennifer Winter | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| 1. Executive Chair 2. Chief Executive Officer 3. Chief Financial Officer 4. Non-Executive Director 5. Non-Executive Director 6. Non-Executive Director | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name
| EKF Diagnostics Holdings plc | |||
b)
| LEI
| 213800DXTF3EAUK1AR05
| |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
Identification code | GB0031509804
| ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1. 22p | 1. 50,000 | ||||
2. 22p | 2. 50,000 | ||||
3. 22p | 3. 50,000 | ||||
4. 22p | 4. 150,000 | ||||
5. 22p | 5. 100,000 | ||||
6. 22p | 6. 150,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | n/a | ||||
- Price | |||||
e)
| Date of the transaction
| 25 March 2025 | |||
f)
| Place of the transaction
| London Stock Exchange, AIMX | |||
Follow the stocks
